Life Sciences Tools and Services
Company Overview of Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is engaged in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. The company offers immunosequencing platform to laboratories around the world to drive research in cancer and other immune-mediated diseases. It also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. Adaptive Biotechnologies Corporation has a strategic research agreement with Argos Therapeutics, Inc. Adaptive Biotechnologies Corporation was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in January 2012. The company w...
1551 Eastlake Avenue East
Seattle, WA 98102
Founded in 2009
Key Executives for Adaptive Biotechnologies Corporation
Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Chief Scientific Officer and Director
Chief Financial Officer, Director and Chairman of Audit Committee
Vice President and General Counsel
Compensation as of Fiscal Year 2016.
Adaptive Biotechnologies Corporation Key Developments
Heat Biologics Selects Adaptive Biotechnologies to Discover Potential Clinical Biomarkers to Advance Novel Immunotherapies
Oct 11 16
Heat Biologics Inc. announced that they have advanced their biomarker discovery collaboration with Adaptive Biotechnologies. Adaptive will use its patented immune profiling assay, immunoSEQ™, to enable an in-depth characterization of the immune response to Heat’s ImPACT and ComPACT-based immunotherapies, including HS-410, Heat’s Phase 2 product candidate for non-muscle invasive bladder cancer. The immunoSEQ Assay, when used to evaluate the mechanism of action of the ImPACT platform, provides a significant biomarker identification opportunity to better select patients and accelerate future enrollment based on immune status.
Adaptive Biotechnologies Corporation Presents at UBS Genomics 2.0 Summit, Aug-11-2016 07:30 AM
Aug 7 16
Adaptive Biotechnologies Corporation Presents at UBS Genomics 2.0 Summit, Aug-11-2016 07:30 AM. Venue: St. Regis Deer Valley, Park City, Utah, United States. Speakers: Chad Robins, Co-Founder, Chief Executive Officer, President and Director.
Argos Therapeutics, Inc. Enters into Strategic Research Agreement with Adaptive Biotechnologies Corporation
Jun 15 16
Argos Therapeutics, Inc. announced that it is partnering with Adaptive Biotechnologies Corporation to study precise response patterns to Argos investigational immunotherapies. Under the agreement, Adaptive will use its patented immune profiling immunoSEQ Assay to enable a more in-depth characterization of the immune response induced by Argos’s lead product candidate, AGS-003, which is currently being studied in the treatment of metastatic renal cell carcinoma, non-small cell lung cancer, and bladder cancer. In addition, Argos is developing its second Arcelis product candidate, AGS-004, for the treatment and the possible eradication of human immunodeficiency virus (HIV) in patients with HIV-infection or acquired immune deficiency syndrome (AIDS). The application of Adaptive’s immune profiling technology in this setting will enable Argos to further characterize with greater precision the transfer of specific genetic signatures from each patient’s HIV, through AGS-004, to a specific immune response against each patient’s unique virus population.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|